Emerging data suggest Retatru tide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could offer a promising step forward for obesity loss . Early patient tests https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026